Nuclear Medicine in Oncology

References

• Alkureishi LWT, Burak Z, Alvarez JA, Ballinger J, Bilde A, Britten AJ, Calabrese L, Chiesa C, Chiti A, Bree R, et al. 2009. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 36:1915–1936.10.1007/s00259-009-1248-0
   PubMed Web of Science ®Google Scholar
• [ARADNJ] The Associated Radiologists, P.A. Radiation-how much am I getting? How can I lower it? [cited April 2015]. Available from: http://www.aradnj.com/radiation-how-much-am-i-getting-how-can-i-lower-it
   Google Scholar
• Bashir U, Mallia A, Stirling J, Joemon J, MacKewn J, Charles-Edwards G, Goh V, Cook GJ. 2015. PET/MRI in oncological imaging: state of the art. Diagnostics. 5:333–357.
   Google Scholar
• Bellis SL. 2011. Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials. 32:4205–4210.10.1016/j.biomaterials.2011.02.029
   PubMed Web of Science ®Google Scholar
• Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJG, Kotzerke J, Hoekstra OS, Pruim J, et al. 2010. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 37:181–200.10.1007/s00259-009-1297-4
   PubMed Web of Science ®Google Scholar
• Bombardieri E, Giammarile F, Aktolun C, Baum RP, Delaloye AB, Maffioli L, Moncayo R, Mortelmans L, Pepe G, Reske SN, et al. 2010. 131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 37:2436–2446.10.1007/s00259-010-1545-7
   PubMed Web of Science ®Google Scholar
• Brenner AI. 2012. The bone scan. Semin Nucl Med. 42:11–26.10.1053/j.semnuclmed.2011.07.005
   PubMed Web of Science ®Google Scholar
• Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caracò C, Cochran AJ, Cook MG, Drzewiecki KT, Essner R, et al. 2009. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 36:1713–1742.10.1007/s00259-009-1228-4
   PubMed Web of Science ®Google Scholar
• Chen X, Wong S. 2014. Cancer theranostics. 1st ed. San Diego, CA: Elsevier, Academic Press; p. 3–8.10.1016/B978-0-12-407722-5.00001-3
   Google Scholar
• Cheng G, Kurita S, Torigian DA, Alavi A. 2011. Current status of sentinel lymph-node biopsy in patients with breast cancer. Eur J Nucl Med Mol Imaging. 38:562–575.10.1007/s00259-010-1577-z
   PubMed Web of Science ®Google Scholar
• Dash A, Chakraborty S, Pillai MR, Knapp FF Jr. 2015. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm. 30:47–71.10.1089/cbr.2014.1741
   PubMed Web of Science ®Google Scholar
• Denoyer D, Pouliot N. 2013. Radionuclide theranostics in cancer. J Mol Imaging Dynam. 4:e104. Available from: http://www.omicsonline.org/open-access/radionuclide-theranostics-in-cancer-2155-9937.1000e104.pdf
   Google Scholar
• Disselhorst JA, Brom M, Laverman P, Slump CH, Boerman OC, Oyen WJG, Gotthardt M, Visser EP. 2010. Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med. 51:610–617.10.2967/jnumed.109.068858
   PubMed Web of Science ®Google Scholar
• [EATRIS] European Infrastructure for Translational Medicine [cited July 2016]. Available from: www.eatris.eu
   Google Scholar
• Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. 1999. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 141:443–457.10.1530/eje.0.1410443
   PubMed Web of Science ®Google Scholar
• Forrer F, Valkema R, Kwekkeboom DJ, Jong M, Krenning EP. 2007. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 21:111–129.10.1016/j.beem.2007.01.007
   PubMed Web of Science ®Google Scholar
• Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. 2008. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 35:1039–1047.10.1007/s00259-008-0715-3
   PubMed Web of Science ®Google Scholar
• Gijs M, Aerts A, Impens N, Baatout S, Luxen A. 2016. Aptamers as radiopharmaceuticals for nuclear imaging and therapy. Nucl Med Biol. 43:253–271.10.1016/j.nucmedbio.2015.09.005
   PubMed Web of Science ®Google Scholar
• Gnanasegaran G. 2009. Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. Semin Nucl Med. 39:431–442.10.1053/j.semnuclmed.2009.07.005
   PubMed Web of Science ®Google Scholar
• Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, Edenbrandt L, Flotats A, Germano G, Stopar TG, et al. 2008. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging. 35:851–885.10.1007/s00259-007-0694-9
   PubMed Web of Science ®Google Scholar
• Herrmann KA, Kohan AA, Gaeta MC, Rubbert C, Vercher-Conejero JL, Paspulati RM, Antonis K, Mansoori B, Faulhaber PF, Avril N, et al. 2013. PET/MRI: applications in clinical imaging. Curr Radiol Rep. 1:161–176.10.1007/s40134-013-0021-0
   Google Scholar
• Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X. 2007. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov. 2:143–158.10.2174/157489207780832469
   PubMed Web of Science ®Google Scholar
• Krajciova D, Melnik M, Havranek E, Forgacsova A, Mikus P. 2014. Copper compounds in Nuclear Medicine and Oncology. J Coord Chem. 67:1493–1519.10.1080/00958972.2014.915966
   Web of Science ®Google Scholar
• Leeson P, Sabharwal N. 2011. Left ventricular function. In: Leeson Paul, editor. Cardiovascular imaging: Oxford specialist handbooks in cardiology. New York, NY: Oxford University Press; p. 114–123.10.1093/med/9780199568451.001.0001
   Google Scholar
• Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, Tennvall J, Bombardieri E. 2008. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 35:1941–1959.10.1007/s00259-008-0883-1
   PubMed Web of Science ®Google Scholar
• Mikus P, Melnik M, Forgacsova A, Krajciova D, Havranek E. 2014. Gallium compounds in Nuclear Medicine and Oncology. Main Group Met Chem. 37:53–65.
   Web of Science ®Google Scholar
• Neves M, Kling A, Oliveira A. 2005. Radionuclides used for therapy and suggestion for new candidates. J Radioanal Nucl Chem. 266:377–384.10.1007/s10967-005-0920-5
   Web of Science ®Google Scholar
• Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland ØS. 2012. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 48:678–686.10.1016/j.ejca.2011.12.023
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. 2013. Alpha emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369:213–223.10.1056/NEJMoa1213755
   PubMed Web of Science ®Google Scholar
• Perkins AC. 1995. Nuclear medicine safety data from nuclear medicine science and safety. Appendix 2. London: John Libbey; p. 153.
   Google Scholar
• Pfeffer B, Tziros C, Katz RJ. 2009. Current concepts of anthracycline cardiotoxicity: pathogenesis, diagnosis and prevention. Br J Cardiol. 16:85–89.
   Google Scholar
• Plana JC, Galderisi M, Barac A, Ewer M, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, et al. 2014. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 27:911–939.10.1016/j.echo.2014.07.012
   PubMed Web of Science ®Google Scholar
• Roesch F. 2012. Scandium-44: benefits of a long-lived PET radionuclide available from the 44Ti/44Sc generator system. Curr Radiopharm. 5:187–201.10.2174/1874471011205030187
   PubMedGoogle Scholar
• Russell CD, Bischoff PG, Kontzen FN, Rowell KL, Yester MV, Lloyd LK, Tauxe WN, Dubovsky EV. 1985. Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection. J Nucl Med. 26:1243–1247.
   PubMed Web of Science ®Google Scholar
• Srivastava SC. 2007. The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117 m. Braz Arch Biol Technol. 50:49–62.10.1590/S1516-89132007000600007
   Web of Science ®Google Scholar
• Taylor AT. 2007. Kidney. In: Biersack H-J, Freeman LM, editors. Clinical nuclear medicine. Berlin: Springer-Verlag; p. 172–198.10.1007/978-3-540-28026-2
   Google Scholar
• Velikyana I, Sundinc A, Erikssond B, Lundqviste H, Sörensenf J, Bergströmg M, Långström B. 2010. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours – impact of peptide mass. Nucl Med Biol. 37:265–275.10.1016/j.nucmedbio.2009.11.008
   PubMed Web of Science ®Google Scholar
• Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, Cristoforo C, et al. 2010. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 37:2004–2010.10.1007/s00259-010-1512-3
   PubMed Web of Science ®Google Scholar
• Warburg O. 1930. The metabolism of tumors. London: Constable Press.
   Google Scholar
• Yeong CH, Cheng MH, KH NG. 2014. Therapeutic radionuclides in nuclear medicine: current and future prospects. Biomed Biotechnol. 15:845–863.
   Google Scholar
• Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O’Dorisio MS, O’Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ. 2013. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 40:800–816.10.1007/s00259-012-2330-6
   PubMed Web of Science ®Google Scholar